Update on the use of letrozole in breast cancer.

摘要: Endocrine therapy is the mainstay of adjuvant treatment for hormonereceptor-positive early breast cancer. Letrozole a potent third-generation aromatase inhibitor that suppresses plasma estrogen levels to near-undetectable in postmenopausal women. The results well-controlled clinical trials have demonstrated efficacy letrozole over gold-standard treatment, tamoxifen, neoadjuvant and upfront settings placebo extended setting (i.e., following 5 years tamoxifen). Important benefits disease-free survival especially distant been demonstrated, both low- high-risk subgroups patients (e.g., node-positive disease, prior chemotherapy). Both safety cancer are reviewed.